Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Istituto Nazionale dei Tumori, Napoli, Italy

Survival: 6.9 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Gemzar
Country: Italy
City/State/Province: Napoli
Hospital: Istituto Nazionale dei Tumori
Journal: Link
Date: 3/2003

Patients: This Phase III trial involved 698 patients with advanced non-small-cell lung cancer. All patients were age 70 or older. Patients were divided into three groups. Group 1 comprised 233 patients. Group 2 comprised 233 patients. Group 3 comprised 232 patients.

Treatment: Patients in Group 1 were administered the drug vinorelbine (navelbine). Patients in Group 2 were administered the drug gemcitabine (gemzar). Patients in Group 3 were administered both drugs, vinorelbine and gemcitabine.

Toxicity: Grade 4 toxicities for patients in Group 3 included hematologic, infection, fever, fatigue, cardiac, and pulmonary.

Other toxicities (grade 3 and below) included bleeding, nausea/vomiting, diarrhea, mucositis, allergy, skin, extravasation, renal, hepatic, constipation, central neurotoxicity, and peripheral neurotoxicity.

Results: Median survival for patients in Group 3 (vinorelbine and gemcitabine) was 30 weeks (6.9 months).

Support: A number of the authors are associated with one or more pharmaceutical companies including AstraZeneca, Eli Lilly, Roche, Smith-Kline, Bristol-Myers Squibb, and Aventis.

Correspondence: Cesare Gridelli, MD

E-mail to a Friend Email Physician More Information